Skip to main content
PMC home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1998;76(1):25–32.

Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

J D Berman 1, R Badaro 1, C P Thakur 1, K M Wasunna 1, K Behbehani 1, R Davidson 1, F Kuzoe 1, L Pang 1, K Weerasuriya 1, A D Bryceson 1
PMCID: PMC2305623  PMID: 9615494

Abstract

Reported are the results of a study to determine the efficacy and safety of liposomal amphotericin B (AmBisome) for treating visceral leishmaniasis (kala-azar) in several developing countries where the disease is endemic (Brazil, India, and Kenya). At each study site, sequential cohorts of 10 patients each were treated with AmBisome at a dose of 2 mg.kg-1.day-1 (2 MKD). The first cohort received regimen 1:2 MKD on days 1-6 and day 10 (total dose: 14 mg/kg). If the efficacy with this regimen was satisfactory, a second cohort received regimen 2:2 MKD on days 1-4 and 10 (total dose: 10 mg/kg); and a third cohort received regimen 3:2 MKD on days 1, 5, and 10 (total dose: 6 mg/kg). In India, regimens 1, 2, and 3 (which were studied concurrently) each cured 100% of 10 patients. In Kenya, regimen 1 cured all 10 patients, regimen 2 cured 90% of 10 patients, but regimen 3 cured only 20% of 5 patients. In Brazil, regimen 1 was only partially curative: 5 of 13 patients (62%). Therefore, 15 patients were administered regimen 4 (2 MKD for 10 consecutive days; total dose, 20 mg/kg) and 13 patients were cured (83%). These results suggest that for the treatment of kala-azar the following doses of AmBisome should be administered: in India and Kenya, 2 mg/kg on days 1-4 and day 10; and in Brazil, 2 mg/kg on days 1-10.

Full text

PDF
25

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berman J. D., Goad L. J., Beach D. H., Holz G. G., Jr Effects of ketoconazole on sterol biosynthesis by Leishmania mexicana mexicana amastigotes in murine macrophage tumor cells. Mol Biochem Parasitol. 1986 Jul;20(1):85–92. doi: 10.1016/0166-6851(86)90145-3. [DOI] [PubMed] [Google Scholar]
  2. Chulay J. D., Bryceson A. D. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg. 1983 May;32(3):475–479. doi: 10.4269/ajtmh.1983.32.475. [DOI] [PubMed] [Google Scholar]
  3. Davidson R. N., Croft S. L., Scott A., Maini M., Moody A. H., Bryceson A. D. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet. 1991 May 4;337(8749):1061–1062. doi: 10.1016/0140-6736(91)91708-3. [DOI] [PubMed] [Google Scholar]
  4. Davidson R. N., Di Martino L., Gradoni L., Giacchino R., Russo R., Gaeta G. B., Pempinello R., Scott S., Raimondi F., Cascio A. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med. 1994 Feb;87(2):75–81. [PubMed] [Google Scholar]
  5. Davidson R. N., di Martino L., Gradoni L., Giacchino R., Gaeta G. B., Pempinello R., Scotti S., Cascio A., Castagnola E., Maisto A. Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis. 1996 Jun;22(6):938–943. doi: 10.1093/clinids/22.6.938. [DOI] [PubMed] [Google Scholar]
  6. Franke E. D., Llanos-Cuentas A., Echevarria J., Cruz M. E., Campos P., Tovar A. A., Lucas C. M., Berman J. D. Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis. Am J Trop Med Hyg. 1994 Jul;51(1):77–82. doi: 10.4269/ajtmh.1994.51.77. [DOI] [PubMed] [Google Scholar]
  7. Franke E. D., Wignall F. S., Cruz M. E., Rosales E., Tovar A. A., Lucas C. M., Llanos-Cuentas A., Berman J. D. Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis. Ann Intern Med. 1990 Dec 15;113(12):934–940. doi: 10.7326/0003-4819-113-12-934. [DOI] [PubMed] [Google Scholar]
  8. Gasser R. A., Jr, Magill A. J., Oster C. N., Franke E. D., Grögl M., Berman J. D. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis. 1994 Jan;18(1):83–90. doi: 10.1093/clinids/18.1.83. [DOI] [PubMed] [Google Scholar]
  9. Hardie W. D., Wheeler A. P., Wright P. W., Swindell B. B., Bernard G. R. Effect of cyclooxygenase inhibition on amphotericin B-induced lung injury in awake sheep. J Infect Dis. 1992 Jul;166(1):134–138. doi: 10.1093/infdis/166.1.134. [DOI] [PubMed] [Google Scholar]
  10. Levine S. J., Walsh T. J., Martinez A., Eichacker P. Q., Lopez-Berestein G., Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Intern Med. 1991 Apr 15;114(8):664–666. doi: 10.7326/0003-4819-114-8-664. [DOI] [PubMed] [Google Scholar]
  11. Mishra M., Biswas U. K., Jha A. M., Khan A. B. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet. 1994 Dec 10;344(8937):1599–1600. doi: 10.1016/s0140-6736(94)90406-5. [DOI] [PubMed] [Google Scholar]
  12. Mishra M., Biswas U. K., Jha D. N., Khan A. B. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet. 1992 Nov 21;340(8830):1256–1257. doi: 10.1016/0140-6736(92)92952-c. [DOI] [PubMed] [Google Scholar]
  13. Russo R., Nigro L. C., Minniti S., Montineri A., Gradoni L., Caldeira L., Davidson R. N. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect. 1996 Mar;32(2):133–137. doi: 10.1016/s0163-4453(96)91343-2. [DOI] [PubMed] [Google Scholar]
  14. Seaman J., Mercer A. J., Sondorp H. E., Herwaldt B. L. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med. 1996 Apr 1;124(7):664–672. doi: 10.7326/0003-4819-124-7-199604010-00007. [DOI] [PubMed] [Google Scholar]
  15. Thakur C. P. Correction of serum electrolyte imbalance prevents cardiac arrhythmia during amphotericin B administration. Natl Med J India. 1995 Jan-Feb;8(1):13–14. [PubMed] [Google Scholar]
  16. Thakur C. P., Pandey A. K., Sinha G. P., Roy S., Behbehani K., Olliaro P. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: a randomized dose-finding study. Trans R Soc Trop Med Hyg. 1996 May-Jun;90(3):319–322. doi: 10.1016/s0035-9203(96)90271-0. [DOI] [PubMed] [Google Scholar]
  17. Thakur C. P., Sinha G. P., Pandey A. K., Barat D., Singh R. K. Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison. Bull World Health Organ. 1994;72(6):931–936. [PMC free article] [PubMed] [Google Scholar]
  18. Thakur C. P., Sinha G. P., Sharma V., Pandey A. K., Kumar M., Verma B. B. Evaluation of amphotericin B as a first line drug in comparison to sodium stibogluconate in the treatment of fresh cases of kala-azar. Indian J Med Res. 1993 Jul;97:170–175. [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES